Determining the effective dose range of DRP vs. target protein TSP1 is of fundamental importance for the pharmaceutical development of DRP-based medicine prototypes for subsequent preclinical evaluation against specific animal disease models. Here, THBS1 is linked to glycogen storage disease VI.